Uncategorized

Nearly two-thirds of participating accountable care organizations earned payments for their performance last year, according to the CMS.

Analysts also forecast renewed interest in M&A now that large companies have worked through a string of spinoffs.

Inspired by Operation Warp Speed, the new federal program aims to fund development and testing of new therapies that can stay ahead of an evolving virus.

A potential sale for the company comes a month after NextGen agreed to pay $31 million to settle allegations that it violated the False Claims Act.

Los primeros virus informáticos marcaron un hito en la historia de la tecnología, dejando una profunda huella en la ciberseguridad moderna. Estos códigos maliciosos pioneros se infiltraron sigilosamente en sistemas informáticos, desatando el caos y la preocupación …

Merck, known as MSD outside of the United States and Canada, announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 inhibitor, being evaluated for the treatment of adults with hypercholesterolemia.

Zhiyi Biotech announced that the first three subjects have been dosed in the U.S. Phase 1 clinical trial of SK10, an innovative heat-killed Bacteroides fragilis product developed by Zhiyi Biotech for Chemotherapy-induced Diarrhea.

Hangzhou Tigermed Consulting Co., Ltd., a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its interim results for the first half of 2023, ended June 30, 2023.

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., a clinical-stage biotech company committed to advancing antiviral therapies and vaccines, with a primary focus on achieving a functional cure for chronic hepatitis B infection, announced the U.S. Food and Drug Administration has granted clearance for the Investigational New Drug application for a clinical trial on AHB-137.

Laekna, Inc. announced the interim results for the six months ended June 30, 2023, and provided the latest updates on the clinical and preclinical development of its drug candidates.